SCS Stock Overview
Stem Cells Spin S.A. operates as a biotechnology company in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Stem Cells Spin S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.50 |
| 52 Week High | zł0.81 |
| 52 Week Low | zł0.30 |
| Beta | 0.74 |
| 1 Month Change | -4.62% |
| 3 Month Change | 24.00% |
| 1 Year Change | 20.39% |
| 3 Year Change | -52.31% |
| 5 Year Change | 3.33% |
| Change since IPO | -77.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| SCS | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -5.5% | -0.7% | 1.4% |
| 1Y | 20.4% | -18.5% | 26.6% |
Price Volatility
| SCS volatility | |
|---|---|
| SCS Average Weekly Movement | 18.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.8% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: SCS's share price has been volatile over the past 3 months.
Volatility Over Time: SCS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1 | Andrzej Kryzar | stemcellsspin.com.pl |
Stem Cells Spin S.A. operates as a biotechnology company in Poland. It engages in the development, cultivation, and application of stem cells using MIC-1 stem cells for human and veterinary medicine, and dermocosmetics applications. The company offers biodermocosmetics under the Revitacell brand name.
Stem Cells Spin S.A. Fundamentals Summary
| SCS fundamental statistics | |
|---|---|
| Market cap | zł20.50m |
| Earnings (TTM) | -zł154.00k |
| Revenue (TTM) | zł419.32k |
48.9x
P/S Ratio-133.1x
P/E RatioIs SCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCS income statement (TTM) | |
|---|---|
| Revenue | zł419.32k |
| Cost of Revenue | zł44.61k |
| Gross Profit | zł374.71k |
| Other Expenses | zł528.71k |
| Earnings | -zł154.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.0037 |
| Gross Margin | 89.36% |
| Net Profit Margin | -36.73% |
| Debt/Equity Ratio | 1.6% |
How did SCS perform over the long term?
See historical performance and comparison